Adaptimmune Therapeutics is a biotechnology business based in the US. Adaptimmune Therapeutics shares (ADAP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.27 – a decrease of 1.26% over the previous week. Adaptimmune Therapeutics employs 506 staff and has a trailing 12-month revenue of around $179.6 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.27 |
|---|---|
| 52-week range | $0.20 - $1.48 |
| 50-day moving average | $0.30 |
| 200-day moving average | $0.67 |
| Wall St. target price | $1.58 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.30 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.275 from 2025-05-21
| 1 week (2025-05-15) | 3.89% |
|---|---|
| 1 month (2025-04-23) | 5.69% |
| 3 months (2025-02-21) | -50.85% |
| 6 months (2024-11-22) | -58.43% |
| 1 year (2024-05-23) | -72.77% |
|---|---|
| 2 years (2023-05-22) | -78.52% |
| 3 years (2022-05-20) | 1.64 |
| 5 years (2020-05-20) | 5.47 |
Valuing Adaptimmune Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptimmune Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adaptimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.11. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adaptimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $179.6 million |
|---|---|
| Gross profit TTM | $29.6 million |
| Return on assets TTM | -14.69% |
| Return on equity TTM | -275.74% |
| Profit margin | -38.91% |
| Book value | $-0.15 |
| Market Capitalization | $73.7 million |
TTM: trailing 12 months
We're not expecting Adaptimmune Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $0.1951 up to $1.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 2.85. This would suggest that Adaptimmune Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. .
Learn how and where to buy Fannie Mae (FNMA) stock, view trends and see what may be ahead for share holders.
See how and where to buy Freddie Mac (FMCC) stock, view past price performance and learn what’s ahead for shareholders.
Direct indexing lets you replicate the performance of a specific index with potentially more tax efficiency. Learn how to get started here.
A deep dive into the highlights and limitations of Frec.
Explore the best bonuses for opening a new brokerage account.
It can help reduce taxes owed, but it’s not for beginners.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
The ins and outs of bundling stocks with this accessible investing option.
A deep dive into the highlights and limitations of Robinhood.